Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely eval...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021-12-01
|
| Col·lecció: | Frontiers in Oncology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fonc.2021.803133/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|